Morie A. Gertz mainly investigates Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Amyloidosis. Morie A. Gertz has included themes like Immunology and Oncology in his Internal medicine study. The various areas that Morie A. Gertz examines in his Multiple myeloma study include Dexamethasone and Pathology.
His study in Surgery is interdisciplinary in nature, drawing from both Hematology and Clinical trial. The Gastroenterology study combines topics in areas such as Creatinine, Progressive disease, Survival analysis and Neutropenia. The concepts of his Amyloidosis study are interwoven with issues in Nephrotic syndrome, Heart failure, AL amyloidosis and Hematologic Response.
The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Surgery, Amyloidosis and Oncology. Internal medicine and Gastroenterology are frequently intertwined in his study. His studies deal with areas such as Survival rate and Survival analysis as well as Gastroenterology.
His work focuses on many connections between Multiple myeloma and other disciplines, such as Dexamethasone, that overlap with his field of interest in Cyclophosphamide. The study incorporates disciplines such as Immunoglobulin light chain, Amyloid, Primary systemic amyloidosis and Immunoglobulin Light-chain Amyloidosis in addition to Amyloidosis. His Oncology study integrates concerns from other disciplines, such as Waldenstrom macroglobulinemia, Newly diagnosed, Clinical trial and Rituximab.
Morie A. Gertz focuses on Internal medicine, Multiple myeloma, Amyloidosis, Oncology and AL amyloidosis. As part of his studies on Internal medicine, Morie A. Gertz frequently links adjacent subjects like Gastroenterology. His research investigates the connection between Gastroenterology and topics such as Cohort that intersect with problems in Hazard ratio.
His Multiple myeloma research is multidisciplinary, incorporating perspectives in Hematopoietic stem cell transplantation, Newly diagnosed, Survival analysis and Bone marrow. His work carried out in the field of Amyloidosis brings together such families of science as Immunoglobulin light chain, Very Good Partial Response, Transthyretin and Amyloid. His Oncology research incorporates themes from Waldenstrom macroglobulinemia, Clinical trial, Rituximab and Daratumumab.
His primary areas of investigation include Internal medicine, Amyloidosis, Multiple myeloma, AL amyloidosis and Gastroenterology. Many of his studies involve connections with topics such as Oncology and Internal medicine. He interconnects Immunoglobulin light chain, Transthyretin, Polyneuropathy and Amyloid in the investigation of issues within Amyloidosis.
As part of the same scientific family, he usually focuses on Multiple myeloma, concentrating on Hazard ratio and intersecting with Surgery. His AL amyloidosis research includes elements of Survival rate, Stem cell, Retrospective cohort study and Very Good Partial Response. His study on Gastroenterology also encompasses disciplines like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Robert A. Kyle;Morie A. Gertz;Thomas E. Witzig;John A. Lust.
Mayo Clinic Proceedings (2003)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar;S. Vincent Rajkumar;Angela Dispenzieri;Martha Q. Lacy.
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley.
British Journal of Haematology (1998)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S K Kumar;A Dispenzieri;M Q Lacy;M A Gertz.
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
POEMS syndrome: definitions and long-term outcome.
Angela Dispenzieri;Robert A. Kyle;Martha Q. Lacy;S. Vincent Rajkumar.
A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine
Robert A. Kyle;Morie A. Gertz;Philip R. Greipp;Thomas E. Witzig.
The New England Journal of Medicine (1997)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
S. Vincent Rajkumar;Suzanne R. Hayman;Martha Q. Lacy;Angela Dispenzieri.
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
Angela Dispenzieri;Morie A. Gertz;Robert A. Kyle;Martha Q. Lacy.
Journal of Clinical Oncology (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: